Here is where preparation separates successful requests from failed ones
As a result of being peptides, GLP-1 RAs typically have to be given by subcutaneous (s.c.) administration as twice daily (BID) (exenatide) [15, 16], once daily (OD) (lixisenatide [17, 18] and liraglutide [19, 20]) or once weekly (OW) (dulaglutide [21, 22], prolonged-release exenatide [23, 24] and semaglutide [25, 26]) dosing regimens, based on their in vivo half-lives [6]
Lilly and Novo have ramped up production dramatically, and neither drug has returned to the shortage list in more than a year
Kesarwani, K., Gupta, R., & Mukerjee, A
Should You Consider GLP-1 for Weight Loss
Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes